Finance

Beta
Lists
MRVL:CVE
Marvel Biosciences Corp
CA$0.20
-2.50%
(-0.0050) 1D
Jun 9, 4:00:00 PM GMT-4  ·   CAD
All symbols
SymbolPriceChange% Change
Generating top insights for MRVL...
Open
CA$0.22
High
CA$0.22
Low
CA$0.19
Mkt. cap
12.29M
Avg. vol.
95.68K
Volume
51.96K
52-wk high
CA$0.40
52-wk low
CA$0.09
EPS
-CA$0.04
Beta
0.23
Shares outstanding
63.03M
Open
CA$0.22
High
CA$0.22
Low
CA$0.19
Mkt. cap
12.29M
Avg. vol.
95.68K
Volume
51.96K
52-wk high
CA$0.40
52-wk low
CA$0.09
EPS
-CA$0.04
Beta
0.23
Shares outstanding
63.03M
News stories
From sources across the web
About Marvel Biosciences Corp
CEO-
Employees-
Founded2021
HeadquartersCalgary, Alberta, Canada
SectorBiotechnology
Websitemarvelbiotechnology.com
Previous reportsAll values in CAD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CAD
Apr 2025
Jul 2025
Oct 2025
Jan 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
382.00
250.56K
57.46K
5.26K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
232.28K
220.93K
189.29K
245.38K
Operating expense
250.32K
488.69K
252.83K
256.72K
Total operating expenses
250.32K
488.69K
252.83K
256.72K
Operating income
-250.32K
-488.69K
-252.83K
-256.72K
Other non operating income
-25.00K
-531.64K
-10.52K
-14.17K
EBT including unusual items
-257.41K
-1.19M
-342.26K
-295.58K
EBT excluding unusual items
-257.41K
-1.19M
-342.26K
-295.58K
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-257.41K
-1.19M
-342.26K
-295.58K
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
1.86K
72.00
-
-
Interest expense
-34.65K
-161.77K
-56.40K
-56.35K
Net interest expenses
-32.79K
-161.70K
-56.40K
-56.35K
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer